Newsstand | Page 9 | Aplastic Anemia & MDS International Foundation Return to top.

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome

Originally Published: 12/24/2020
Abstract Allogeneic hematopoietic stem cell transplantation is the only potentially curative treatment for patients with myelodysplastic syndrome (MDS), but long-term survival is limited by the risk of transplant-related complications. Short telomere length, mediated by inherited or acquired factors, impairs cellular response to genotoxic and replicative stress and could identify patients at higher risk for toxicity after transplantation. We measured relative telomere length in pretransplant recipient blood samples in 1514 MDS patients and evaluated the association of telomere length with...

Dr. Tony Lin Summarizes Venclexta Data Presented at ASH

Originally Published: 12/21/2020
The all-virtual 62nd ASH Annual Meeting & Exposition highlighted some of the newest data about Venclexta. DocWire News interviewed Tony Lin, Pharm.D., a Senior Scientific Director with AbbVie US medical affairs, to discuss this more in-depth. Dr. Lin is a pharmacist by training and has been working in the oncology therapeutic area and biopharmaceutical industry for over 12 years. DocWire News: What patients is Venclexta indicated to treat? Dr. Lin: In the U.S., VENCLEXTA is approved for multiple blood cancers, including for adults with chronic lymphocytic leukemia (CLL) or small...

Overcoming Clinical Challenges Associated With TP53-Mutant MDS, AML

Originally Published: 12/15/2020
TP53-mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival. Across TP53-altered MDS and AML, standard therapies for wild-type disease have been of minimal benefit, but a wave of investigational agents currently in development offers promise for patients with TP53-altered malignancies, which affect 8% to 12% and 5% to 10% of patients with MDS and AML, respectively. In contrast with wild-type, FLT3-, and IDH1/2-...

Clinical Challenges: Paroxysmal Nocturnal Hemoglobinuria — Complement inhibitors a major advance but not a cure

Originally Published: 12/09/2020
Paroxysmal nocturnal hemoglobinuria (PNH) is an extremely rare, acquired, life-threatening disease of the blood. The name comes from one of the clinical consequences of the disease -- the breakdown of red blood cells and consequent release of hemoglobin into the urine. It often results in dark-colored urine most prominently seen in the morning. PNH is caused by deficiency in glycophosphatidylinositol-anchored biosynthesis, leaving red blood cells susceptible to destruction -- i.e., hemolysis -- by the body's complement system. Though the condition is rare, its diagnosis is straightforward,...

Guadecitabine Maintenance Therapy Shows Promise in High Risk MDS/AML Patients

Originally Published: 12/08/2020
Guadecitabine (SGI-110), when given as maintenance therapy following allogeneic stem cell transplantation (allo-SCT), showed promising relapse-free survival rates (RFS) with manageable safety in high-risk patients with myelodysplastic syndromes/acute myeloid leukemia (MDS/AML), according to data presented by Betul Oran, MD, MS, Stem Cell Transplantation and Cellular Therapy, The University of Texas, MD Anderson Cancer Center, Houston, TX, at the virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.  “Disease relapse remains to be one of the major reasons [for[...

Oral Azacitidine Improves, Sustains Health-Related QoL in AML

Originally Published: 12/06/2020
Treatment with the oral agent showed sustained health-related quality of life compared with placebo in patients with acute myeloid leukemia, according to results of the phase 3 QUAZAR AML-001 trial. Treatment with oral azacitidine (CC-486) showed sustained health-related quality of life (HRQoL), compared with placebo, in patients with acute myeloid leukemia (AML), according to results of the phase 3 QUAZAR AML-001 trial.1 Results from HRQoL analysis of the QUAZAR AML-001 trial were presented by Gail J. Roboz, MD, professor of Medicine, Weill Cornell Medical College, during the American...

Significant Racial, Ethnic Related Socioeconomic Disparities Influence Survival in AML

Originally Published: 12/06/2020
Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area. Significant disparities were found between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia (AML) in the Chicago metropolitan area , according to findings from a multilevel analysis presented virtually during the 2020 ASH Annual Meeting. Moreover, socioeconomic tract information, including...

Bone Marrow Transplant Recipients During Childhood at Increased Risk for Severe Chronic Health Conditions

Originally Published: 12/05/2020
Patients who underwent allogeneic bone marrow transplantation (BMT) as children were at increased risk for severe or life-threatening chronic health conditions. These findings were presented during the American Society of Hematology (ASH) 62nd Annual Meeting and Exposition. For this study, 848 patients who survived at least 2 years after a BMT during early adulthood or adolescence (aged 22 years or younger) and their siblings or parents (n=515) were recruited. Participants were assessed by questionnaire for sociodemographic characteristics and health status. At the time of study, 563 of the...

GTB-3550 TriKE Stimulates Natural Killer Cell Function in MDS and AML

Originally Published: 12/05/2020
December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia. GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), according to data from initial dose cohorts of a phase 1/2 trial (NCT03214666) presented during the 2020 ASH Annual Meeting & Exposition. Results showed that the GTB-3550 TriKE, when administered at a daily dose of 5 mcg/kg in a patient with therapy-...
Share with addtoany.com.